| BioTrends Releases TreatmentTrends: US Nephrology, an Ongoing ... - PharmaLive.com (press release) |
|
|
And among those aware of Affymax's Hematide, currently in development, interest is high. The IV iron market, on the other hand, is likely to see more ... |